Abstract
EuroAlliance (a consortium of Alfa Wassermann SpA, Lacer SA and Merckle GmbH) is developing licofelone, a dual cyclooxygenase and 5-lipoxygenase inhibitor for the potential treatment of inflammatory disorders including osteoarthritis.
MeSH terms
-
Acetates / adverse effects
-
Acetates / pharmacokinetics
-
Acetates / pharmacology*
-
Acetates / therapeutic use
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Cyclooxygenase Inhibitors / adverse effects
-
Cyclooxygenase Inhibitors / pharmacokinetics
-
Cyclooxygenase Inhibitors / pharmacology*
-
Cyclooxygenase Inhibitors / therapeutic use
-
Humans
-
Inflammation / drug therapy*
-
Inflammation / pathology
-
Lipoxygenase Inhibitors
-
Osteoarthritis / drug therapy*
-
Osteoarthritis / pathology
-
Pyrroles / adverse effects
-
Pyrroles / pharmacokinetics
-
Pyrroles / pharmacology*
-
Pyrroles / therapeutic use
-
Structure-Activity Relationship
Substances
-
Acetates
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cyclooxygenase Inhibitors
-
Lipoxygenase Inhibitors
-
Pyrroles
-
licofelone